Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Rating of “Reduce” from Brokerages

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received an average rating of “Reduce” from the eight analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $18.8571.

A number of equities analysts recently weighed in on IART shares. UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Thursday, June 18th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Finally, Truist Financial boosted their target price on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY purchased a new position in shares of Integra LifeSciences in the second quarter valued at $61,766,000. Rubric Capital Management LP lifted its holdings in shares of Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after buying an additional 2,710,262 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Integra LifeSciences by 2,059.1% in the second quarter. California State Teachers Retirement System now owns 1,358,620 shares of the life sciences company’s stock valued at $24,401,000 after acquiring an additional 1,295,695 shares during the period. Bank of America Corp DE grew its stake in Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after acquiring an additional 589,408 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Integra LifeSciences during the 2nd quarter worth approximately $8,723,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART traded down $0.06 during mid-day trading on Monday, hitting $16.68. 19,893 shares of the company’s stock were exchanged, compared to its average volume of 883,356. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The stock’s 50-day simple moving average is $17.99 and its 200-day simple moving average is $14.07. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -185.30, a price-to-earnings-growth ratio of 1.41 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts expect that Integra LifeSciences will post 2.46 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.